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old. After adjusting for confounders, patients with COPD and
asthma were twice as likely to use FSC than those with Asthma
along (OR 1.99, 95% CI 1.73–2.29); patients with COPD alone
were 66% less likely to receive FSC than those with Asthma
along (OR 0.34, 95% CI 0.28–0.41). African-Americans were a
third less likely to be prescribed FSC than Caucasians (OR 0.69;
95% CI 0.61–0.78), and females about a third more likely than
males to use FSC (OR 1.35; 95% CI 1.16–1.57). Age was not a
signiﬁcant predictor at the 0.05 level. CONCLUSION: The
propensity to be prescribed FSC is signiﬁcantly higher in patients
with COPD/asthma than those with either disease alone. Race
and gender signiﬁcantly affect access to FSC in MMMCO, even
after adjusting for comorbidities. Cost to the patient was not a
factor, as the copayment was $1 for any prescription.
STROKE—Clinical Outcomes Studies
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OBJECTIVES: To determine the epidemiological risk factors
associated with stroke, examine their inﬂuence on stroke-related
costs, and identify areas that need further research. METHODS:
A systematic literature search was performed (1996–2006) using
an exhaustive list of relevant search terms to identify articles
published on epidemiology of stroke and associated risk factors,
costs of stroke and economic impact of risk factors on stroke.
Studies were identiﬁed through electronic Medline® and
PubMed® searches. Manual review of bibliographies allowed
determination of additional articles. RESULTS: Out of a total of
41 included studies, 26 studies focused on stroke-associated risk
factors, while 15 studies examined the economic burden of
stroke. Apart from age and race [African-Americans have the
highest per-capita stroke costs ($25,782), followed by Hispanics
($17,201)], hypertension was the most prevalent clinical risk
factor (58.1% to 75%), followed by diabetes. Relative risk for
stroke was higher in women (increase of 2–6.5 fold) as compared
to men (1.5–2 fold) with diabetes. Renal dysfunction, pregnancy,
inﬂammation and infection, depression, chronic headache and
migraine, metabolic syndrome, cancer, and AIDS were other risk
factors identiﬁed. Total cost of stroke in United States was found
to be approximately $58 billion [2006 American Heart Associ-
ation]. Mean total cost per individual approximated $125,000.
Subarachnoid hemorrhage was reported to be the costliest stroke
sub-type. Hospitalizations and medications were the major cost
components in stroke treatment. Studies have linked few risk
factors, such as smoking and higher age, to increased stroke
treatment costs, but the impact of the majority of risk factors on
stroke costs has not been examined. CONCLUSION: Stroke has
a signiﬁcant economic impact on society, due to its morbidity
and mortality burden. However, few studies have examined the
impact of individual stroke-associated risk factors on stroke
costs. Further research demonstrating economic link of common
risk factors with stroke is warranted.
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OBJECTIVES: Subarachnoid hemorrhage (SAH) is a rare but
catastrophic event, occurring in ∼10/100,000 people, which may
result in permanent brain damage or death. Although treatment
protocols for surgical or endovascular management of SAH have
been published, widespread differences exist in patient manage-
ment. METHODS: The MedStat Marketscan databases were
used for 2000–2004 to study medical utilization for non-
traumatic SAH. Data included commercially insured and
Medicare-eligible claimants. Hospitalization records were exam-
ined for patients ages 18 and older who had a primary diagno-
sis of SAH (ICD-9 430) without any indication of trauma (n =
3241). If a hospital stay was followed by another hospitalization
which started on the date of discharge, the two were treated as
a single episode of care. Rates of surgical clipping and/or
endovascular coiling (“treatment” to secure the aneurysm), inpa-
tient death rates, day of any surgical treatment, length of stay,
and hospital readmissions were examined. RESULTS: Seventy
percent of admissions for SAH were ages <65, and 35% were
treated. Among those over age 65, only 13% were treated. 14%
of SAH patients died during the initial hospitalization. Mortal-
ity rates were lower for those treated at all ages. Among sur-
vivors treated, 45% were treated on the day of admission, and
about one-third were treated the day after admission. Among
survivors, the median length of stay was 6 days for those without
treatment, and nearly twice as long for patients who were
clipped, coiled or both. 5% of patients were readmitted to hos-
pital, with a median of 17 days between ﬁrst and second admis-
sions. CONCLUSION: Most patients presenting at the hospital
with non-traumatic SAH received no surgical or endovascular
treatment. The 35% treatment rate for SAH. is considerably
lower than in other countries, raising the possibility that patient
treatment may not be optimal in the U.S.
STROKE—Cost Studies
PST3
THE IMPACT OF WIDESPREAD ACCESS TO ORGANIZED
STROKE CARE IN CANADA
Caro JJ1, Huybrechts KF1, Kongnakorn T1, Ozer Stillman I1,
Sharma M2
1Caro Research Institute, Concord, MA, USA, 2The Ottawa Hospital,
Ottawa, ON, Canada
OBJECTIVES: Despite solid evidence, measures for prevention,
treatment and other health practices that could reduce mortal-
ity, disability and costs are not being used routinely in Canada.
An economic model was developed to formally assess the poten-
tial clinical and economic impact of implementing a com-
prehensive stroke program. METHODS: A discrete event
simulation was designed to assess the implications of various
stroke strategies deﬁned in terms of the usage of organized stroke
units and clot-busting therapies, access to rehabilitation, stroke
awareness and prevention campaigns. Stroke incidence, modiﬁed
by whatever prevention practices are analyzed, is applied to the
Canadian population to create the simulated patients with
stroke. Each patient’s management is simulated according to his
characteristics and the interventions available given the strategy
under consideration. Over time, patients are exposed to risks of:
death, new stroke, change in functional level, and transfer to
another location of care. Each event is processed in terms of its
clinical consequences, resource use and cost. Data were obtained
from the Registry of the Canadian Stroke Network, the Cana-
dian Heart Health Survey, Statistics Canada and the Institute for
Clinical and Evaluative Sciences. RESULTS: Implementation of
widespread prevention and awareness campaigns would result in
∼127,000 fewer initial strokes over 20 years. Access to organized
